Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Synthetic Peptide Non-Covalently Transports Cancer Drugs Across the Blood-Brain Barrier

By BiotechDaily International staff writers
Posted on 18 Jun 2014
Cancer researchers have used a novel synthetic peptide to transport chemotherapeutic compounds and other small molecules across the blood-brain barrier and into the brains of mice.

The transport peptide, K16ApoE, comprised sixteen lysine residues and 20 amino acids corresponding to the LDLR (low density lipoprotein receptor)-binding domain of apolipoprotein E (ApoE). Investigators at the Mayo Clinic (Rochester, MN, USA) had demonstrated previously that by mimicking a ligand-receptor system, K16ApoE could deliver three different proteins (beta-galactosidase, IgG, and IgM) in a non-covalent fashion across the blood-brain barrier. To their knowledge this was the first report demonstrating successful delivery of various proteins across the blood-brain barrier that did not involve chemically linking the proteins with a carrier entity.

In the current study, the investigators delivered chemotherapeutics and other agents into the brains of mice either by injecting the carrier peptide and the drugs separately or as a mixture via the femoral vein. A modification of the method comprised injection of K16ApoE pre-mixed with cetuximab, followed by injection of a small-molecule drug.

The investigators reported in the May 21, 2014, online edition of the journal PLOS ONE that seven-of-seven different small molecules were successfully delivered to the brain via K16ApoE. Depending on the injection method, brain uptake was 34–50-fold greater for cisplatin and 54–92-fold greater for methotrexate with K16ApoE than without. Visually intense brain-uptake of the dyes Evans Blue, Light Green SF, and Crocein scarlet was also achieved. Direct intracranial injection of Evans Blue showed locally restricted distribution of the dye in the brain, whereas K16ApoE-mediated intravenous injection resulted in the distribution of the dye throughout the brain.

"We know that some chemotherapeutic agents can kill brain tumor cells when they are outside the brain (as in a laboratory test). But because the agents cannot cross the blood-brain barrier, they are not able to kill brain tumor cells inside the brain. With the peptide carrier, these agents can now get into the brain and potentially kill the tumor cells," said senior author Dr. Robert Jenkins a neurology researcher at the Mayo Clinic.

Related Links:

Mayo Clinic



BIOSIGMA S.R.L.
RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.